{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:50:46Z","timestamp":1791125446099,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL) in patients with follicular lymphoma (FL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>From 1972 to 1999, 325 patients were diagnosed with FL at St Bartholomew's Hospital (London, United Kingdom). With a median follow-up of 15 years, progression occurred in 186 patients and biopsy-proven transformation in 88 of the 325. The overall repeat biopsy rate was 70%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The risk of histologic transformation (HT) by 10 years was 28%, HT not yet having been observed after 16.2 years. The risk was higher in patients with advanced stage (P = .02), high-risk Follicular Lymphoma International Prognostic Index (FLIPI; P = .01), and International Prognostic Index (IPI; P = .04) scores at diagnosis. Expectant management (as opposed to treatment being initiated at diagnosis) also predicted for a higher risk of HT (P = .008). Older age (P = .005), low hemoglobin level (P = .03), high lactate dehydrogenase (P &lt; .0001), and high-risk FLIPI (P = .01) or IPI (P = .003) score at the time of first recurrence were associated with the diagnosis of HT in a biopsy performed at that time. The median survival from transformation was 1.2 years. Patients with HT had a shorter overall survival (P &lt; .0001) and a shorter survival from progression (P &lt; .0001) than did those in whom it was not diagnosed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advanced stage and high-risk FLIPI and IPI scores at diagnosis correlate with an increased risk of HT. This event strongly influences the outcome of patients with FL by shortening their survival. There may be a subgroup of patients in whom HT does not occur.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2006.09.3260","type":"journal-article","created":{"date-parts":[[2007,5,7]],"date-time":"2007-05-07T20:40:56Z","timestamp":1178570456000},"page":"2426-2433","source":"Crossref","is-referenced-by-count":346,"title":["Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"],"prefix":"10.1200","volume":"25","author":[{"given":"Silvia","family":"Montoto","sequence":"first","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew John","family":"Davies","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Matthews","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calaminici","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Norton","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Amess","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vinnicombe","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Waters","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama Z.S.","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.1.11"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V59.2.258.258"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1587"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl162"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi024"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.10.1470"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(81)90070-X"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1177\/000456328101800408"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2427"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.527"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381105849"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.055"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.2307\/2529177"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression models and life tables. J R Stat Assoc 34:187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Davies AJ, Lee AM, Taylor C, et al: A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 8:1459,2005-1465,","DOI":"10.1038\/sj.leu.2403802"},{"key":"R23","unstructured":"Davies AJ, Iqbal S, Fitzgibbon J, et al: Homozygosity mapping by genome-wide SNP analysis of the transformation of follicular lymphoma (FL) to diffuse larger B-cell lymphoma (TXDLBCL). Ann Oncol 16:106,2005,  (abstr 234)"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Al-tourah A, Gill K, Hoskins PJ, et al: The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. J Clin Oncol 24:424s,2006,  (suppl; abstr 7510)","DOI":"10.1200\/jco.2006.24.18_suppl.7510"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1361::AID-CNCR20>3.0.CO;2-W"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.942"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058157"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf119"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.09.3260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:07:55Z","timestamp":1653494875000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.09.3260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,10]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2007,6,10]]}},"alternative-id":["10.1200\/JCO.2006.09.3260"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.09.3260","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1088359.541399","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,10]]}}}